SHCBP1 Antibody

What is SHCBP1 and what characteristics should researchers consider when selecting antibodies against it?

SHCBP1 is a cytoplasmic protein of 672 amino acid residues with a molecular mass of 75.7 kDa that plays significant roles in cellular proliferation, growth, and differentiation signaling pathways . When selecting antibodies, researchers should consider:

• Target specificity: Confirm the antibody recognizes the canonical 75.7 kDa SHCBP1 protein

• Species reactivity: SHCBP1 has orthologs in mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken; select antibodies with appropriate cross-reactivity based on your model system

• Application compatibility: Verify the antibody is validated for your specific application (Western blot, ELISA, IHC)

• Epitope location: Consider whether N-terminal, C-terminal, or internal epitopes are most appropriate for your research question

What are the most effective applications for SHCBP1 antibodies in research?

SHCBP1 antibodies can be effectively employed across multiple experimental platforms:

• Western Blotting: The most widely used application for detecting SHCBP1 protein expression and evaluating protein size

• ELISA: Useful for quantitative measurement of SHCBP1 levels in biological fluids or cell lysates

• Immunohistochemistry: Enables visualization of SHCBP1 expression patterns in tissue sections

• Immunofluorescence: Particularly valuable for subcellular localization studies

For optimal results in proliferation studies, researchers should combine Western blot with immunofluorescence analysis of markers like Ki67, as demonstrated in cervical cancer research .

How should researchers validate SHCBP1 antibody specificity for their experimental systems?

Methodological approach to antibody validation:

• Positive and negative controls: Include tissues/cell lines known to express high levels of SHCBP1 (e.g., cervical cancer cell lines like SiHa) versus those with lower expression (e.g., CaSki cells)

• Knockout/knockdown verification: Use stable SHCBP1-silenced cells to confirm antibody specificity

• Overexpression systems: Utilize SHCBP1-overexpressing cells as positive controls

• Multiple antibody comparison: When possible, compare results using antibodies targeting different epitopes

• Molecular weight confirmation: Verify detection at the expected 75.7 kDa band for human SHCBP1

What baseline expression patterns of SHCBP1 should researchers expect across different tissue types?

SHCBP1 exhibits distinct expression patterns that researchers should consider when designing experiments:

• Normal tissues: Generally lower expression in quiescent tissues and growth-arrested cells

• Cancer tissues: Significantly upregulated in multiple cancer types, particularly in cervical squamous cell carcinoma and lymphoid neoplasm diffuse large B-cell lymphoma

• Cell cycle dependence: Expression increases during entry into S phase and in response to stimulators of cell cycle progression

• Bone marrow: Notably high expression even in normal bone marrow tissue

When designing experiments, researchers should account for these baseline differences to properly interpret results.

How can researchers effectively investigate SHCBP1's role in cancer cell proliferation and cell cycle regulation?

To thoroughly examine SHCBP1's impact on proliferation, implement this methodological approach:

• Loss and gain-of-function models: Establish stable SHCBP1-silenced and SHCBP1-overexpressing cancer cell lines

• Proliferation assays: Utilize MTT assays to quantitatively measure proliferation rates in modified cell lines

• Cell cycle analysis: Perform flow cytometric analysis to determine SHCBP1's effect on cell cycle distribution, particularly focusing on G1/S transition

• Molecular marker assessment: Examine expression of cell cycle regulators (cyclin D1, p21) via Western blotting to elucidate mechanism

• Ki67 immunofluorescence: Conduct IFA of Ki67 to visualize and quantify proliferative cells

This integrated approach revealed that SHCBP1 overexpression promotes S phase entry while SHCBP1 knockdown induces G1 phase arrest in cervical cancer models .

What experimental design is optimal for studying SHCBP1's relationship with cancer stemness properties?

The following methodological framework is recommended:

• Gene expression analysis: Measure mRNA levels of stemness markers (CD44, CD133, NANOG, OCT4) using RT-qPCR in SHCBP1-manipulated cells

• Sphere formation assays: Quantify the ability of cancer cells to form spheroids under non-adherent conditions as a functional measure of stemness

• Self-renewal assessment: Evaluate serial passage capacity of spheroids derived from SHCBP1-overexpressing versus control cells

• Protein expression confirmation: Validate stemness marker expression at protein level via Western blotting

• In vivo tumor initiation: Assess tumor-initiating capacity using limiting dilution assays with SHCBP1-modified cells

Research has demonstrated that SHCBP1 overexpression significantly increases stemness marker expression in cervical cancer cells, confirming its role in maintaining cancer stem cell-like properties .

How should researchers approach studying the relationship between SHCBP1 and the NF-κB signaling pathway?

A comprehensive experimental strategy includes:

• Pathway component analysis: Measure phosphorylation status and total protein levels of key NF-κB pathway components (p65, IκBα) by Western blotting in SHCBP1-manipulated cells

• Nuclear translocation assessment: Perform nuclear/cytoplasmic fractionation followed by Western blotting or immunofluorescence to track p65 nuclear translocation

• Transcriptional activity measurement: Utilize NF-κB luciferase reporter assays to quantify pathway activation

• Target gene expression: Analyze NF-κB target gene expression via RT-qPCR

• Pathway inhibitors: Confirm specificity by treating with NF-κB pathway inhibitors

Evidence indicates that SHCBP1 activates the NF-κB signaling pathway in cervical cancer cells, enhancing nuclear translocation of p65 and promoting NF-κB-mediated gene transcription .

What techniques are most effective for investigating the functional interaction between SHCBP1 and EIF5A?

To thoroughly characterize the SHCBP1-EIF5A axis, implement this methodological approach:

• Expression correlation analysis: Determine if EIF5A expression changes with SHCBP1 manipulation using RT-qPCR and Western blotting

• Co-immunoprecipitation: Assess potential physical interaction between SHCBP1 and EIF5A proteins

• Rescue experiments: Silence EIF5A in SHCBP1-overexpressing cells to determine if EIF5A mediates SHCBP1's effects

• Functional readouts: Measure proliferation, stemness, and NF-κB activation in rescue experiments

• Pathway analysis: Identify common downstream targets of both proteins

Research has demonstrated that EIF5A knockdown reverses the pro-proliferative effects and NF-κB pathway activation induced by SHCBP1 overexpression in cervical cancer cells, confirming that SHCBP1 functions through EIF5A .

How can researchers effectively analyze SHCBP1's relationship with tumor immune microenvironment?

A comprehensive approach includes:

• Correlation analysis: Assess relationships between SHCBP1 expression and immune cell infiltration markers using bioinformatics tools and public datasets (TCGA)

• Immunosuppressive gene profiling: Measure correlation between SHCBP1 and immunosuppressive genes (TGFBR1, PD-L1, TGFB1)

• Tumor-associated macrophage (TAM) analysis: Quantify TAM infiltration markers in relation to SHCBP1 expression

• Multi-parameter flow cytometry: Characterize immune cell populations in SHCBP1-high versus SHCBP1-low tumor models

• Functional immune assays: Assess T-cell activation and cytotoxicity in co-culture systems with SHCBP1-manipulated cancer cells

Research has demonstrated that SHCBP1 expression positively correlates with TAMs and immunosuppressive genes, suggesting its role in creating an immunosuppressive tumor microenvironment .

What are the recommended protocols for using SHCBP1 antibodies in Western blotting?

For optimal Western blot results with SHCBP1 antibodies:

• Sample preparation:

  • Use RIPA buffer with protease/phosphatase inhibitors

  • Load 20-30 μg of total protein per lane

  • Include positive controls (e.g., SiHa cervical cancer cells with high SHCBP1 expression)

• Electrophoresis and transfer:

  • Use 8-10% SDS-PAGE gels to properly resolve the 75.7 kDa SHCBP1 protein

  • Transfer to PVDF membranes at 100V for 90 minutes in cold transfer buffer

• Antibody incubation:

  • Block with 5% non-fat milk in TBST for 1 hour

  • Incubate with primary SHCBP1 antibody (1:1000 dilution recommended) overnight at 4°C

  • Wash thoroughly (3×10 minutes with TBST)

  • Incubate with HRP-conjugated secondary antibody (1:5000) for 1 hour

• Detection considerations:

  • Use enhanced chemiluminescence detection

  • Expose for multiple time points to capture optimal signal

  • Verify molecular weight using appropriate protein standards

What experimental design is recommended for studying SHCBP1's prognostic value in cancer?

To rigorously evaluate SHCBP1's prognostic significance:

Research has confirmed SHCBP1 as a poor prognostic marker across multiple cancer types, with high expression associated with reduced survival .

What are the best methods for creating and validating SHCBP1 knockdown and overexpression models?

For creating reliable SHCBP1-modified research models:

• Knockdown strategies:

  • Use lentiviral shRNA delivery for stable silencing

  • Design multiple shRNA sequences targeting different regions of SHCBP1 mRNA

  • Include non-targeting shRNA controls

  • Validate knockdown efficiency by RT-qPCR and Western blotting (target >70% reduction)

• Overexpression approaches:

  • Clone full-length human SHCBP1 cDNA into appropriate expression vectors

  • Use cell lines with relatively low endogenous SHCBP1 (e.g., CaSki cells)

  • Include empty vector controls

  • Confirm overexpression by RT-qPCR and Western blotting

• Functional validation:

  • Assess proliferation rates using MTT assays

  • Evaluate cell cycle distribution by flow cytometry

  • Measure expression of known SHCBP1-regulated genes

How can researchers accurately analyze SHCBP1's role in drug resistance mechanisms?

A systematic approach to studying SHCBP1-mediated drug resistance includes:

• Drug sensitivity profiling:

  • Compare IC50 values of anti-cancer drugs between SHCBP1-high and SHCBP1-low cells

  • Use databases like GDSC (Genomics of Drug Sensitivity in Cancer) to identify potentially resistant drugs

  • Test multiple drug classes to identify specific resistance patterns

• Resistance mechanism investigation:

  • Analyze changes in drug efflux transporters, apoptotic pathways, and DNA repair mechanisms

  • Assess activation of alternative survival pathways in SHCBP1-overexpressing cells

  • Measure drug accumulation and metabolism

• Combination therapy evaluation:

  • Test SHCBP1 inhibition in combination with standard chemotherapeutics

  • Assess synergistic, additive, or antagonistic effects using combination indices

Research has demonstrated that high SHCBP1 expression is associated with resistance to various anti-tumor drugs, suggesting its potential as a therapeutic target to overcome resistance .